NORMAL SITUATION

Jay Therapeutics

Export PDF
Financial year 2026 · closed on 17/07/2026
Net result
70,3 k €
+178.2% YoY
Gross margin
-14,5 k €
-20.2% YoY
Equity
10,2 k €
+117.1% YoY

Company — Normal situation.

Strike-off: 06 août 2026

What does Jay Therapeutics do?

Jay Therapeutics is a Public limited company incorporated in 2021.

Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0771.305.101
Incorporation
12/07/2021
Legal form
Public limited company
Contributed capital
2 600 000,00 €
Latest accounts
17/07/2026
Signals
ProfitableSolid equityPositive cashflow
View the BCE/KBO Public Search record →
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 5 financial years

20262025202420232022
Income statement
Gross margin-14,5 k €-12,1 k €-27,2 k €-96,3 k €-160,7 k €
EBITDA-14,5 k €-12,6 k €-28,3 k €-96,8 k €-161,7 k €
Operating result-34,5 k €-78,2 k €-209,9 k €-812,9 k €-1,7 M €
Net result70,3 k €-89,9 k €-158,1 k €-773,9 k €-1,6 M €
Balance sheet
Equity10,2 k €-60 k €29,8 k €188 k €961,9 k €
Total assets10,2 k €166,1 k €249,5 k €261,2 k €973,2 k €
Cash10,2 k €23,3 k €42,1 k €81 k €778,6 k €
Debts–226,1 k €219,7 k €73,2 k €11,3 k €
Governance

Board of directors

Seen on filing of 17/07/2026 · 2 active

Active mandates

Griet Vanpoucke

Director · since 12 juillet 2021

Active
V-Bio Fund 2

Director · since 12 juillet 2021 · 0759.685.291

Represented by Katja Rosenkranz

Active
Annual accounts

Full financial information

20262025202420232022
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202601/01/202501/01/202401/01/202312/07/2021
Closing of the financial year17/07/202631/12/202531/12/202431/12/202331/12/2022
Length of the financial year7 months12 months12 months12 months18 months
Filing date24/08/202627/05/202603/06/202511/06/202427/06/2023
General meeting17/07/202626/05/202627/05/202528/05/202430/05/2023
Currency of the financial yearEUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

5 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Abridged model17/07/202617/07/202624/08/2026DutchPDF
Abridged model31/12/202526/05/202627/05/2026DutchPDF
Abridged model31/12/202427/05/202503/06/2025DutchPDF
Abridged model31/12/202328/05/202411/06/2024DutchPDF
Abridged model31/12/202230/05/202327/06/2023DutchPDF
Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 17/07/2026 · 2 active

Active mandates

Griet Vanpoucke

Director · since 12 juillet 2021

Active
V-Bio Fund 2

Director · since 12 juillet 2021 · 0759.685.291

Represented by Katja Rosenkranz

Active
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Dissolution07/08/2026
    RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ... - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates30/11/2022
    KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
    PDF
  • Capital / shares23/07/2021
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - KAPITAAL - AANDELEN
    PDF
  • Other14/07/2021
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2026
    Annual accounts 202670,3 k €↑
  2. 2025
    Annual accounts 2025-89,9 k €↑
  3. 2024
    Annual accounts 2024-158,1 k €↑
  4. 2023
    Annual accounts 2023-773,9 k €↑
  5. 2022
    Annual accounts 2022-1,6 M €
  6. 12/07/2021
    IncorporationPublic limited company